Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROSULA CLK is a prescription topical kit developed by Bradley Pharmaceuticals (through its Doak Dermatologics subsidiary) for the treatment of acne vulgaris, acne rosacea, and seborrheic dermatitis. The kit consists of two distinct components: ROSULA Clarifying Wash and A-FIL Cream. The wash component contains 10% sodium sulfacetamide, 4% sulfur, and urea, providing antibacterial and keratolytic effects. Sodium sulfacetamide acts as a sulfonamide antibiotic that inhibits bacterial growth by competing with p-aminobenzoic acid (PABA), while sulfur serves as a keratolytic agent to reduce inflammation and promote skin turnover. The A-FIL Cream component is a tinted sunscreen containing 5% meradimate and 5% titanium dioxide (SPF-25) to protect the skin from UV radiation, which can exacerbate rosacea and acne symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ROSULA CLK.